Print this page
Make An Appointment
+
Book Appointment Online with select physicians.
Request Appointment Online to schedule with one of our coordinators.
1.888.IUHEALTH for
Same-Day Primary Care Appointments.
If you are experiencing a medical emergency, please call 9-1-1.
triangle

IU Health Methodist Cancer Center Research Group

Our expertly trained, private-practice physicians offer the best possible care and treatment. With highly advanced technology and state-of-the-art treatment methods at their disposal, Indiana University Health Methodist Hospital doctors offer patients treatment options based on sound diagnoses and the latest research. Our patients also benefit from a variety of support and health and wellness programs—ensuring a well-rounded, coordinated approach to tackling illness and disease.

Learn more about the Methodist Cancer Center Research Group >>

Clinical Trials Conducted at IU Health Methodist Hospital

IU Health Methodist Cancer Center is actively involved in conducting clinical trials for many types of cancer. Clinical trials are crucial to finding new and better ways to not only prevent cancer, but most importantly, to treat it when it occurs.

The following are current clinical trials being performed at the IU Health Methodist Cancer Center:

BREAST

A Phase III Trial Comparing Trastuzumab Given Concurrently with Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy
Study #: NSABP B-43
Principal Investigator: Alex Yeh, MD


A Phase III Trial of Accelerated Whole Breast Irradiation with Hypofractionation Plus Concurrent Boost Versus Standard Whole Breast Irradiation Plus Sequential Boost for Early-Stage Breast Cancer
Study #: RTOG 1005
Principal Investigator: Alex Yeh, MD

BRAIN

A Phase II Trial of Hippocampal Avoidance During Whole Brain Radiotherapy for Brain Metastases
Study #: RTOG 0933
Principal Investigator: Alex Yeh, MD

Randomized, Phase II, Double-Blind, Placebo-Controlled Trial of Conventional Chemoradiation and Adjuvant Temozolomide Plus Cediranib Versus Conventional Chemoradiation and Adjuvant Temozolomide Plus Placebo In Patients With Newly Diagnosed Glioblastoma
Study #: RTOG 0837
Principal Investigator: Alex Yeh, MD

CENTRAL NERVOUS SYSTEM

Phase II Trial of Observation For Low-Risk Meningiomas And of Radiotherapy For Intermediate-And High-Risk Meningiomas
Study #: RTOG 0539
Principal Investigator: Alex Yeh, MD

GASTROINTESTINAL

A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel, Cisplatin, and Radiation for Patients with Esophageal Cancer who are Treated without Surgery
Study #: RTOG 0436
Principal Investigator: Alex Yeh, MD

GENITOURINARY

A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy
Study #: RTOG 0534
Principal Investigator: Alex Yeh, MD

HEAD AND NECK

A Phase III Study of Postoperative Radiation Therapy (IMRT) +/-Cetuximab for Locally-Advanced Resected Head and Neck Cancer
Study #: RTOG 0920
Principal Investigator: Alex Yeh, MD


IUSCC Clinical Trials

Open Only To Clarian Hematology Oncology at Methodist Patients

LUNG

A8081014 *Tumor Block* Phase III, Randomized, Open-Label Study of the Efficacy and Safety of Crizotinib vs. Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in Previously Untreated Patients with Non-Squamous Carcinoma of the Lung Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase Gene Locus
Study #: 1011004368
Principal Investigator: Shadia Jalal, MD
CRS: Lynn McCranor

ARQ 197-A-U302 *Tumor Block* A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ197 Plus Erlotinib Vs. Placebo Plus Erlotinib in Previously Treated Subject with Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (NSCLC)
Study #: 1105005331
Principal Investigator: Lawrence Einhorn, MD
CRS: Matt Burns

E5508 Three-Arm Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carbonplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC
Study #: 1105005334
Principal Investigator: Lawrence Einhorn, MD
CRS: Matt Burns

GU

E2809 Phase II, Randomized Study of MK-2206-Bicalutamide Combination in Patients with Rising PSA at High-Risk of Progression after Primary Therapy
Study #: 1105005343
Principal Investigator: Noah Hahn, MD
CRS: Rhoda Loman

VEG113387 A Randomized, Double-Blind, Placebo-Controlled Phae III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects with Localized or Locally Advanced RCC Following Nephrectomy
Study #: 1105005371
Principal Investigator: Theodore Logan, MD
CRS: Dylan Cregar

HEMATOLOGY

OMB112517 A Phase III, Open Label, Randomized, Multicenter Trial of Ofatumumab Maintenance Treatment versus No Further Treatment in Subjects with Relapsed Chronic Lymphocytic Leukemia (CLL) Who Have Responded to Induction Therapy
Study #: 1011003958
Principal Investigator: Jose Azar, MD
CRS: Rebecca Runkel

BREAST

BRE09-146 PARP Inhibition after Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer or ER/PR +, HER2 negative with known BRACA 1/2 Mutations
Study #: 1011003554
Principal Investigator: Kathy Miller, MD
CRS: Becca Graffis

MA32 A Phase III Radnomized Trial of Metformin versus Placebo on Recurrence and Survival in Early Stage Breast Cancer
Study #: 1106005988
Principal Investigator: Kathy Miller, MD
CRS: Kisha Horan

IMCLCP20-0903 An Open-Label, Multicenter, Randomized Phase II Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Mets Breast CA Patients Previously Treated With Anthracycline and Taxane Therapy
Study #: 05005388
Principal Investigator: Kathy Miller, MD
CRS: Becca Graffis

GI

IUCRO-0298 An Open-label Dose-escalation Study with Lenalidomide in Combination with Fixed Dose of Nexavar® for the Treatment of Hepatocellular Carcinoma
Study #: 1105005453
Principal Investigator: Rakesh Vinayek, MD
CRS: Matt Burns

E7208 A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy
Study #: 1107006369
Principal Investigator: Elena Chiorean, MD
CRS: Matt Burns

CA046 A Randomized Phase III Study of Weekly ABI-007 plus Gemcitabine vs. Gemcitabine Alone in Patients with Metastatic Adenocarcinoma of the Pancreas
Study #: 1011003050
Principal Investigator: Elena Chiorean, MD
CRS: Matt Burns

LYMPHOMA

CC-5013-MCL-001 A Phase II Multicenter, Single-Arm, Open-Label Study to Determine the Efficacy and Safety of Single-Agent Lenalidomide (Revlimid®) in Subjects with Mantle Cell NHL Who Have Relapsed or Progressed after Treatment with Bortezomib or Are Refractory to Bortezomib
Study #: 0811-09/1105005489
Principal Investigator: Michael Robertson, MD
CRS: Rebecca Runkel

CRAD001N2301 A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching placebo after patients have achieved complete response with first-line rituximab-chemotherapy.
Study #: 1011003299
Principal Investigator: Michael Robertson, MD
CRS: Bobbie Frye

LYM08-134 Phase II Study of Fludarabine, Bortezombine, Bortezomib and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
Study #: 1011003130
Principal Investigator: Shivani Srivastava, MD
CRS: Bobbie Frye

In compliance with procedures of the IU Health Methodist Cancer Program, each study appearing on this list has IRB approval for website posting.

For more information contact:

IU Health Methodist Hospital
Cooperative Group Oncology Program (CGOP)
1633 N. Capitol Ave. #301
Indianapolis, Indiana 46202
317.962.8288